C-ENNZTornado Therapeutics
rapalogs, mTOR inhibition
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
All companiesC-ENNZ
C-ENNZC-ENNZrapalogs, mTOR inhibition
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Tornado Therapeutics states that targeting mTOR with safer, more effective rapamycin analogues could treat and prevent disease while extending healthy lifespan. The company presents rapamycin as the best-validated therapeutic for extending healthy lifespan across multiple preclinical species and argues that rapamycin and rapalogs therefore have potential to extend human healthspan by preventing or treating aging-related disease. It further states that its selectively engineered rapalogs should improve safety and efficacy versus currently approved mTOR inhibitors.
SourceTornado Therapeutics states that targeting mTOR with improved rapamycin analogues can treat and prevent aging-related disease and extend healthy lifespan. The company presents rapamycin as the best validated therapy for lifespan extension across multiple preclinical species and argues that safer, more effective, selectively designed rapalogs could translate that potential into humans across several clinical indications.
SourceThe company states that selectively inhibiting mTOR is a strong and credible path to extending human healthspan, arguing that mTOR inhibitors are the best-validated longevity therapeutics and that a new class of safer, more effective mTOR inhibitors should be developed for this purpose. It also frames rapamycin and related rapalogs as established examples within this therapeutic class.
SourceTornado Therapeutics states that mTOR inhibitors are the best-validated longevity therapeutics and that selective, safer, more effective mTOR inhibitors can be developed to extend human healthspan. Its position is that rapamycin and related mTOR-targeting drugs already have strong clinical and preclinical support, and that improved structural analogues with novel selectivity profiles may deliver better safety and efficacy for human use.
Source